Follow the people · Insider
George Kemble
George Kemble files insider transactions with the SEC as an executive chairman of Sagimet Biosciences (SGMT). We hold 3 disclosed purchases and sales filed since 20 July 2023, 3 of them in the last 90 days.
- Files forSGMT
- Disclosed buys and sells3 in all, 3 in the last 90 days
- Last disclosure17 August 2026
Positions held
1 post we hold — a term names its own dates; a run of filings only says when they filed- Filed 18 July 2023 — 14 August 2026Executive Chairman · Sagimet Biosciences (SGMT)35 Form 4 lines · source: SEC Form 4
Everything they disclosed
35 entries, newest first — one per disclosure report, one per Form 4 line- exercised options over 326,618 shares of Sagimet BiosciencesSEC Form 417 August 2026Series A Common Stock · traded 14 August 2026 · filed 17 August 2026
- exercised options over 24,369 shares of Sagimet BiosciencesSEC Form 417 August 2026Series A Common Stock · traded 14 August 2026 · filed 17 August 2026
- ▼ sold on the open market 350,987 shares of Sagimet BiosciencesSEC Form 417 August 2026Series A Common Stock · traded 14 August 2026 · filed 17 August 2026
- exercised options over 326,618 shares of Sagimet Biosciences (a derivative holding)SEC Form 417 August 2026Stock Option (Right to Buy) · traded 14 August 2026 · filed 17 August 2026
- exercised options over 24,369 shares of Sagimet Biosciences (a derivative holding)SEC Form 417 August 2026Stock Option (Right to Buy) · traded 14 August 2026 · filed 17 August 2026
- exercised options over 9,751 shares of Sagimet BiosciencesSEC Form 412 August 2026Series A Common Stock · traded 11 August 2026 · filed 12 August 2026
- exercised options over 10,455 shares of Sagimet BiosciencesSEC Form 412 August 2026Series A Common Stock · traded 11 August 2026 · filed 12 August 2026
- ▼ sold on the open market 20,206 shares of Sagimet BiosciencesSEC Form 412 August 2026Series A Common Stock · traded 11 August 2026 · filed 12 August 2026
- exercised options over 9,751 shares of Sagimet Biosciences (a derivative holding)SEC Form 412 August 2026Stock Option (Right to Buy) · traded 11 August 2026 · filed 12 August 2026
- exercised options over 10,455 shares of Sagimet Biosciences (a derivative holding)SEC Form 412 August 2026Stock Option (Right to Buy) · traded 11 August 2026 · filed 12 August 2026
- ▼ sold on the open market 18,844 shares of Sagimet BiosciencesSEC Form 422 July 2026Series A Common Stock · traded 20 July 2026 · filed 22 July 2026
- was granted 39,567 shares of Sagimet Biosciences (a derivative holding)SEC Form 415 June 2026Stock Option (Right to Buy) · traded 12 June 2026 · filed 15 June 2026
- ▼ sold on the open market 37,688 shares of Sagimet BiosciencesSEC Form 421 November 2025Series A Common Stock · traded 20 November 2025 · filed 21 November 2025
- was granted 32,250 shares of Sagimet Biosciences (a derivative holding)SEC Form 410 June 2025Stock Option (Right to Buy) · traded 9 June 2025 · filed 10 June 2025
- ▼ sold on the open market 23,625 shares of Sagimet BiosciencesSEC Form 425 July 2024Series A Common Stock · traded 23 July 2024 · filed 25 July 2024
- ▼ sold on the open market 14,062 shares of Sagimet BiosciencesSEC Form 423 July 2024Series A Common Stock · traded 19 July 2024 · filed 23 July 2024
- was granted 150,750 shares of Sagimet BiosciencesSEC Form 421 November 2023Series A Common Stock · traded 17 November 2023 · filed 21 November 2023
- exercised options over 5,630 shares of Sagimet Biosciences (a derivative holding)SEC Form 48 September 2023Stock Option (Right to Buy) · traded 7 September 2023 · filed 8 September 2023
- exercised options over 5,630 shares of Sagimet BiosciencesSEC Form 48 September 2023Series A Common Stock · traded 7 September 2023 · filed 8 September 2023
- returned to the issuer 5,630 shares of Sagimet Biosciences (a derivative holding)SEC Form 420 July 2023Stock Option (Right to Buy) · traded 18 July 2023 · filed 20 July 2023
- was granted 5,630 shares of Sagimet Biosciences (a derivative holding)SEC Form 420 July 2023Stock Option (Right to Buy) · traded 18 July 2023 · filed 20 July 2023
- returned to the issuer 3,179 shares of Sagimet Biosciences (a derivative holding)SEC Form 420 July 2023Stock Option (Right to Buy) · traded 18 July 2023 · filed 20 July 2023
- was granted 3,179 shares of Sagimet Biosciences (a derivative holding)SEC Form 420 July 2023Stock Option (Right to Buy) · traded 18 July 2023 · filed 20 July 2023
- returned to the issuer 7,147 shares of Sagimet Biosciences (a derivative holding)SEC Form 420 July 2023Stock Option (Right to Buy) · traded 18 July 2023 · filed 20 July 2023
- was granted 7,147 shares of Sagimet Biosciences (a derivative holding)SEC Form 420 July 2023Stock Option (Right to Buy) · traded 18 July 2023 · filed 20 July 2023
- returned to the issuer 26,352 shares of Sagimet Biosciences (a derivative holding)SEC Form 420 July 2023Stock Option (Right to Buy) · traded 18 July 2023 · filed 20 July 2023
- was granted 26,352 shares of Sagimet Biosciences (a derivative holding)SEC Form 420 July 2023Stock Option (Right to Buy) · traded 18 July 2023 · filed 20 July 2023
- returned to the issuer 367,824 shares of Sagimet Biosciences (a derivative holding)SEC Form 420 July 2023Stock Option (Right to Buy) · traded 18 July 2023 · filed 20 July 2023
- was granted 367,824 shares of Sagimet Biosciences (a derivative holding)SEC Form 420 July 2023Stock Option (Right to Buy) · traded 18 July 2023 · filed 20 July 2023
- returned to the issuer 46,432 shares of Sagimet Biosciences (a derivative holding)SEC Form 420 July 2023Stock Option (Right to Buy) · traded 18 July 2023 · filed 20 July 2023
- was granted 46,432 shares of Sagimet Biosciences (a derivative holding)SEC Form 420 July 2023Stock Option (Right to Buy) · traded 18 July 2023 · filed 20 July 2023
- returned to the issuer 526,332 shares of Sagimet Biosciences (a derivative holding)SEC Form 420 July 2023Stock Option (Right to Buy) · traded 18 July 2023 · filed 20 July 2023
- was granted 526,332 shares of Sagimet Biosciences (a derivative holding)SEC Form 420 July 2023Stock Option (Right to Buy) · traded 18 July 2023 · filed 20 July 2023
- returned to the issuer 21,173 shares of Sagimet Biosciences (a derivative holding)SEC Form 420 July 2023Stock Option (Right to Buy) · traded 18 July 2023 · filed 20 July 2023
- was granted 21,173 shares of Sagimet Biosciences (a derivative holding)SEC Form 420 July 2023Stock Option (Right to Buy) · traded 18 July 2023 · filed 20 July 2023
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.